In order for our site to display correctly you will need a newer version of your web browser.
The following browsers support numerous web standards including CSS,XHTML, and the DOM (a universal means of controlling the behavior of web pages):
- Netscape v7 or higher (all platforms), Mozilla FireFox (Windows), Camino (Mac OS X), Galeon (Linux GNOME Desktop) or other browser stemming from the Mozilla.org project.
- Opera v7 or higher (Windows, Linux)
- Apple's Safari (Mac OS X)
- Konqueror (Linux KDE Desktop)
- Microsoft Internet Explorer v6 or higher (Windows) or v5 or higher (Macintosh)
Please note that this is not intended be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Finding Cures. Saving Children.
Non-Therapeutic Protocol
MARB: Molecular Analysis of Retinoblastoma
Type of Protocol/Clinical Study
Associated Solid Tumor Studies : Retinoblastoma
Description
Retinoblastoma is a childhood tumor that affects the retina portion of the eye. These tumors form because of a gene inactivation that occurs before birth. This gene is known as RB1. Children who inherit one abnormal copy of RB1 are likely to develop retinoblastoma affecting both eyes. Children who randomly inherit the gene usually have retinoblastoma involving only one eye. Treatment for retinoblastoma includes removing the diseased eye during an operation in the more advanced cases.
Researchers want to look at a sample of the tumor tissues removed during the operation. They want to learn more about what makes these tumor cells grow and why. They would also like to collect a sample of the participants’ blood, and some information about the child’s age, family history and the stage of the tumor to compare with other tissues and blood samples obtained in the study.
Objective
- To study retinoblastoma cells in the laboratory
- To see if any of these studies are associated with the chance of the tumor spreading
- To compare findings in blood and cancer cells
Eligibility
- Participant is undergoing surgery for suspected retinoblastoma
- Participant is able to provide 1 teaspoon of blood
Principal Investigator
Michael Dyer, PhD
Amendment 2.0 dated 6.26.08, IRB approved 9.09.08
The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.
